Macrophages and therapeutic resistance in cancer.

How neoplastic cells respond to therapy is not solely dependent on the complexity of the genomic aberrations they harbor but is also regulated by numerous dynamic properties of the tumor microenvironment. Identifying and targeting critical pathways that improve therapeutic efficacy by bolstering anti-tumor immune responses holds great potential for improving outcomes and impacting long-term patient survival. Macrophages are key regulators of homeostatic tissue and tumor microenvironments. Therefore, therapeutics impacting macrophage presence and/or bioactivity have shown promise in preclinical models and are now being evaluated in the clinic. This review discusses the molecular/cellular pathways identified so far whereby macrophages mediate therapeutic responses.

[1]  F. Geissmann,et al.  Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors , 2014, Nature.

[2]  M. Willson,et al.  CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans , 2011 .

[3]  J. Ochoa,et al.  l-Arginine Consumption by Macrophages Modulates the Expression of CD3ζ Chain in T Lymphocytes1 , 2003, The Journal of Immunology.

[4]  F. Geissmann,et al.  Constant replenishment from circulating monocytes maintains the macrophage pool in adult intestine , 2014, Nature Immunology.

[5]  Shigeyoshi Itohara,et al.  Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis , 2000, Nature Cell Biology.

[6]  Wilfrid Boireau,et al.  Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth , 2012, Nature Medicine.

[7]  P. Gimotty,et al.  Hypoxia-inducible factor 2alpha regulates macrophage function in mouse models of acute and tumor inflammation. , 2010, The Journal of clinical investigation.

[8]  J. Flynn,et al.  Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapy. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  Kenji Suzuki,et al.  Prognostic Impact of CD204-Positive Macrophages in Lung Squamous Cell Carcinoma: Possible Contribution of Cd204-Positive Macrophages to the Tumor-Promoting Microenvironment , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[10]  Anne-Marie Cleton-Jansen,et al.  Tumor-Infiltrating Macrophages Are Associated with Metastasis Suppression in High-Grade Osteosarcoma: A Rationale for Treatment with Macrophage Activating Agents , 2011, Clinical Cancer Research.

[11]  K. Mertz,et al.  Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis , 2014, Nature.

[12]  Heng Zhang,et al.  Infiltration of diametrically polarized macrophages predicts overall survival of patients with gastric cancer after surgical resection , 2015, Gastric Cancer.

[13]  Robert A. Weinberg,et al.  Tumor Metastasis: Molecular Insights and Evolving Paradigms , 2011, Cell.

[14]  L. Coussens,et al.  Differential macrophage programming in the tumor microenvironment. , 2012, Trends in immunology.

[15]  I. Tannock,et al.  Drug resistance and the solid tumor microenvironment. , 2007, Journal of the National Cancer Institute.

[16]  William King,et al.  High-density gene expression analysis of tumor-associated macrophages from mouse mammary tumors. , 2009, The American journal of pathology.

[17]  J. Joyce,et al.  IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. , 2010, Genes & development.

[18]  E. Brogi,et al.  Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. , 2011, Genes & development.

[19]  R. Jain.  Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[20]  Thomas A. Wynn,et al.  Macrophage biology in development, homeostasis and disease , 2013, Nature.

[21]  A. Yoshimura,et al.  IL-1β and TNFα-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis. , 2011, International immunology.

[22]  Na Zhang,et al.  Deletion of Vascular Endothelial Growth Factor in myeloid cells accelerates tumorigenesis , 2008, Nature.

[23]  M. Giacca,et al.  Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels , 2007, Cell.

[24]  Luigi Naldini,et al.  Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. , 2005, Cancer cell.

[25]  J. Pollard,et al.  Vascular endothelial growth factor restores delayed tumor progression in tumors depleted of macrophages , 2007, Molecular oncology.

[26]  A. Sica,et al.  A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). , 2006, Blood.

[27]  Jing Xu,et al.  Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1 , 2009, The Journal of experimental medicine.

[28]  K. Flaherty,et al.  The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFα. , 2014, Cancer discovery.

[29]  Karin Jirström,et al.  Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. , 2011, Cancer discovery.

[30]  H. Runnels,et al.  Increased serum enzyme levels associated with kupffer cell reduction with no signs of hepatic or skeletal muscle injury. , 2011, The American journal of pathology.

[31]  Craig Murdoch,et al.  The role of myeloid cells in the promotion of tumour angiogenesis , 2008, Nature Reviews Cancer.

[32]  M. Dewhirst,et al.  Bevacizumab-Induced Alterations in Vascular Permeability and Drug Delivery: A Novel Approach to Augment Regional Chemotherapy for In-Transit Melanoma , 2012, Clinical Cancer Research.

[33]  J. Delord,et al.  Implication of Tumor Microenvironment in Chemoresistance: Tumor-Associated Stromal Cells Protect Tumor Cells from Cell Death , 2012, International journal of molecular sciences.

[34]  Liu Changling,et al.  CCL 18 promotes epithelial-mesenchymal transition , invasion and migration of pancreatic cancer cells in pancreatic ductal adenocarcinoma , 2015 .

[35]  N. Rosenthal,et al.  Progressive replacement of embryo-derived cardiac macrophages with age , 2014, The Journal of experimental medicine.

[36]  Jeffrey W Pollard,et al.  Tumor-associated macrophages: from mechanisms to therapy. , 2014, Immunity.

[37]  Jiahuai Han,et al.  Cathepsin B Is Involved in the Trafficking of TNF-α-Containing Vesicles to the Plasma Membrane in Macrophages1 , 2008, The Journal of Immunology.

[38]  P. Carmeliet,et al.  HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. , 2011, Cancer cell.

[39]  L. Naldini,et al.  Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. , 2011, Cancer cell.

[40]  Luke A. Gilbert,et al.  DNA Damage-Mediated Induction of a Chemoresistant Niche , 2010, Cell.

[41]  A. Mantovani,et al.  Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm , 2010, Nature Immunology.

[42]  Laura J. Esserman,et al.  Leukocyte composition of human breast cancer , 2011, Proceedings of the National Academy of Sciences.

[43]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[44]  D. McMillan,et al.  The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer. , 2012, Cancer treatment reviews.

[45]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[46]  T. Graeber,et al.  Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. , 2014, Cancer research.

[47]  T. Bieber,et al.  Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. , 2014, The New England journal of medicine.

[48]  Yuquan Wei,et al.  Prognostic Significance of Tumor-Associated Macrophages in Solid Tumor: A Meta-Analysis of the Literature , 2012, PloS one.

[49]  F. Balkwill.  Tumour necrosis factor and cancer , 2009, Nature Reviews Cancer.

[50]  C. Di Serio,et al.  TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice. , 2011, The Journal of clinical investigation.

[51]  Matthew J. Craig,et al.  The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment. , 2009, Neoplasia.

[52]  P. Bradding,et al.  The Tissue Microlocalisation and Cellular Expression of CD163, VEGF, HLA-DR, iNOS, and MRP 8/14 Is Correlated to Clinical Outcome in NSCLC , 2011, PloS one.

[53]  Luigi Naldini,et al.  FcRgamma activation regulates inflammation-associated squamous carcinogenesis. , 2010, Cancer cell.

[54]  R. Jain,et al.  Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner , 2012, Nature nanotechnology.

[55]  G. Tosato,et al.  Interleukin-1 induces interleukin-6 production in peripheral blood monocytes. , 1990, Blood.

[56]  G. Bergers.  HIFα induces the recruitment of bone marrow‐derived vascular modulatory cells to regulate tumor angiogenesis , 2008 .

[57]  E. Eruslanov,et al.  Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer. , 2012, American journal of translational research.

[58]  Shu-Min Lin,et al.  Tumor‐associated macrophages correlate with response to epidermal growth factor receptor‐tyrosine kinase inhibitors in advanced non‐small cell lung cancer , 2012, International journal of cancer.

[59]  Hua Yu,et al.  Revisiting STAT3 signalling in cancer: new and unexpected biological functions , 2014, Nature Reviews Cancer.

[60]  B. Faddegon,et al.  TH2-Polarized CD4+ T Cells and Macrophages Limit Efficacy of Radiotherapy , 2015, Cancer Immunology Research.

[61]  P. Pereira,et al.  Contribution of IL-17–producing γδ T cells to the efficacy of anticancer chemotherapy , 2011, The Journal of Experimental Medicine.

[62]  P. De Baetselier,et al.  Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. , 2010, Cancer research.

[63]  M. Banerjee,et al.  Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. , 2009, Blood.

[64]  T. Luedde,et al.  Senescence surveillance of pre-malignant hepatocytes limits liver cancer development , 2011, Nature.

[65]  Sebastian Amigorena,et al.  Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. , 2014, Cancer cell.

[66]  Christina S. Leslie,et al.  CSF-1R inhibition alters macrophage polarization and blocks glioma progression , 2013, Nature Medicine.

[67]  Hideaki Tahara,et al.  Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells , 2011, Proceedings of the National Academy of Sciences.

[68]  J. Pollard,et al.  Microenvironmental regulation of metastasis , 2009, Nature Reviews Cancer.

[69]  Michael C. Ostrowski,et al.  An ets2-driven transcriptional program in tumor-associated macrophages promotes tumor metastasis. , 2010, Cancer research.

[70]  Kristian Pietras,et al.  High interstitial fluid pressure — an obstacle in cancer therapy , 2004, Nature Reviews Cancer.

[71]  Sebastian Amigorena,et al.  Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity. , 2014, Cancer cell.

[72]  J. Pollard.  Trophic macrophages in development and disease , 2009, Nature Reviews Immunology.

[73]  R. Hruban,et al.  Immunohistochemical expression of CD68 antigen in human peripheral blood T cells. , 1994, Human pathology.

[74]  P. Pereira,et al.  Contribution of IL-17–producing γδ T cells to the efficacy of anticancer chemotherapy , 2011, The Journal of experimental medicine.

[75]  Mina J Bissell,et al.  The tumor microenvironment is a dominant force in multidrug resistance. , 2012, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[76]  J. Pollard,et al.  Myeloid WNT7b mediates the angiogenic switch and metastasis in breast cancer. , 2014, Cancer research.

[77]  Hua Yu,et al.  IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway , 2009, The Journal of experimental medicine.

[78]  A. Lusis,et al.  Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. , 2010, Blood.

[79]  Gefeng Zhu,et al.  B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma , 2006, The Journal of experimental medicine.

[80]  S. Zelenay,et al.  Adaptive immunity after cell death. , 2013, Trends in immunology.

[81]  L. Esserman,et al.  Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome , 2011, Breast Cancer Research and Treatment.

[82]  S. Asgharzadeh,et al.  Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. , 2009, The Journal of clinical investigation.

[83]  Andrew V. Nguyen,et al.  Colony-Stimulating Factor 1 Promotes Progression of Mammary Tumors to Malignancy , 2001, The Journal of experimental medicine.

[84]  Jianhua Huang,et al.  A Role for VEGF as a Negative Regulator of Pericyte Function and Vessel Maturation , 2008, Nature.

[85]  Ruth J. Muschel,et al.  A Distinct Macrophage Population Mediates Metastatic Breast Cancer Cell Extravasation, Establishment and Growth , 2009, PloS one.

[86]  M. Diamond,et al.  IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia , 2012, Nature Immunology.

[87]  J. Blay,et al.  Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. , 2014, Cancer cell.

[88]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[89]  R. A. Evans,et al.  CD40 immunotherapy for pancreatic cancer , 2013, Cancer Immunology, Immunotherapy.

[90]  G. Sethi,et al.  Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. , 2010, Biochimica et biophysica acta.

[91]  Robert A. Gatenby,et al.  Environment-mediated drug resistance: a major contributor to minimal residual disease , 2009, Nature Reviews Cancer.

[92]  M. Rehli,et al.  Expression of CD68 in Non‐Myeloid Cell Types , 2008, Scandinavian journal of immunology.

[93]  Mohammad Tabrizi,et al.  A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models , 2010, Molecular Cancer Therapeutics.

[94]  M. Karin,et al.  IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. , 2014, Seminars in immunology.

[95]  Srinivas Nagaraj,et al.  Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.

[96]  R. Schwendener,et al.  Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach , 2006, British Journal of Cancer.

[97]  K. Guo,et al.  CCL18 promotes epithelial-mesenchymal transition, invasion and migration of pancreatic cancer cells in pancreatic ductal adenocarcinoma. , 2015, International journal of oncology.

[98]  G. Tosato,et al.  Interleukin-1 induces interleukin-6 production in peripheral blood monocytes. , 1990 .

[99]  M. Mazzone,et al.  Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. , 2013, Cancer cell.

[100]  G. Cline,et al.  Functional polarization of tumour-associated macrophages by tumour-derived lactic acid , 2014, Nature.

[101]  E. Stanley,et al.  Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts. , 2006, Cancer research.

[102]  L. Coussens,et al.  CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+ T cells , 2013, Oncoimmunology.

[103]  C. Lewis,et al.  Macrophage regulation of tumor responses to anticancer therapies. , 2013, Cancer cell.

[104]  G. Trinchieri,et al.  Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. , 2005, Cancer research.

[105]  G. Zhu,et al.  Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. , 2007, Cancer research.

[106]  G. Randolph,et al.  Origin and functions of tissue macrophages. , 2014, Immunity.

[107]  L. Peyrin-Biroulet,et al.  Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study , 2014, Gut.

[108]  D. Linehan,et al.  CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. , 2015, Cancer research.

[109]  Jonathan B. Mitchem,et al.  Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. , 2013, Cancer research.

[110]  H. Yao,et al.  A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis. , 2014, Cancer cell.

[111]  手塚 建一,et al.  骨芽細胞様細胞が産生する Macrophage colony-stimulating factor は後期分化にある破骨細胞のサバイバルファクターである , 1997 .

[112]  Kaibo Duan,et al.  Human Dermal CD14+ Cells Are a Transient Population of Monocyte-Derived Macrophages , 2014, Immunity.

[113]  Y. Iwamoto,et al.  Macrophage infiltration predicts a poor prognosis for human ewing sarcoma. , 2011, The American journal of pathology.

[114]  A. Alavi,et al.  A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma , 2013, Clinical Cancer Research.

[115]  O. Beretta,et al.  Macrophages in human colorectal cancer are pro‐inflammatory and prime T cells towards an anti‐tumour type‐1 inflammatory response , 2012, European journal of immunology.

[116]  Stephen Mok,et al.  CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. , 2013, Cancer research.

[117]  Lee， Jk,et al.  Lebrikizumab treatment in adults with asthma. , 2011 .

[118]  L. Coussens,et al.  Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. , 2010, Cancer research.

[119]  F. Geissmann,et al.  Correction: Corrigendum: Constant replenishment from circulating monocytes maintains the macrophage pool in the intestine of adult mice , 2014, Nature Immunology.

[120]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[121]  B. Faddegon,et al.  T H 2-polarized CD4 + T cells and macrophages limit efficacy of radiation therapy , 2015 .

[122]  Masahiro Inoue,et al.  An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. , 2004, The Journal of clinical investigation.

[123]  Rakesh K. Jain,et al.  Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors , 2004, Cancer Research.

[124]  X. Mo,et al.  Macrophage Colony-Stimulating Factor Augments Tie2-Expressing Monocyte Differentiation, Angiogenic Function, and Recruitment in a Mouse Model of Breast Cancer , 2014, PloS one.

[125]  A. Mildner,et al.  Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. , 2013, Immunity.

[126]  T. Tedder,et al.  Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice. , 2011, The Journal of clinical investigation.

[127]  Jae-Hyun Park,et al.  Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. , 2012, Cancer cell.

[128]  L. Coussens,et al.  B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas. , 2014, Cancer cell.

[129]  P. Carmeliet,et al.  Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population. , 2014, Cancer research.

[130]  L. Coussens,et al.  CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. , 2009, Cancer cell.

[131]  M. Takeya,et al.  Clinical significance of macrophage heterogeneity in human malignant tumors , 2013, Cancer science.

[132]  R. Palmqvist,et al.  The Distribution of Macrophages with a M1 or M2 Phenotype in Relation to Prognosis and the Molecular Characteristics of Colorectal Cancer , 2012, PloS one.

[133]  V. Gocheva,et al.  Deficiency of the macrophage growth factor CSF-1 disrupts pancreatic neuroendocrine tumor development , 2012, Oncogene.

[134]  Vivien W. Chan,et al.  Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. , 2014, Cancer cell.

[135]  Bruce H. Hasegawa,et al.  The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans , 2007, Proceedings of the National Academy of Sciences.